![Cheryl Cohen](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Cheryl Cohen
Director/Board Member at CELLDEX THERAPEUTICS, INC.
Net worth: 1 M $ as of 30/05/2024
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Joseph H. Gardner | M | 68 |
Aerpio Therapeutics, Inc.
![]() Aerpio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aerpio Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases. The firm develops small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Its two lead programs include a tie-2 activator for diabetic macular edema and vascular leak, and a hypoxia-inducible factor 1-a stabilizer for wound healing and the treatment of inflammatory bowel disease. The company was founded by Joseph H. Gardner and Robert Shalwitz in 2011 and is headquartered in Cincinnati, OH. | 17 years |
Barry Simon | M | 59 | 17 years | |
John McBride | M | 72 |
Tokai Pharmaceuticals, Inc.
![]() Tokai Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tokai Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel proprietary therapies for the treatment of prostate cancer and hormonally driven diseases. The company was founded by Joseph A. Yanchik, Gregory L. Verdine, and Seth L. Harrison on March 26, 2004 and is headquartered in Boston, MA. | 10 years |
Anthony Marucci | M | 62 | 41 years | |
Sam Martin | M | 53 | 15 years | |
Patrick Soon-Shiong | M | 71 | 10 years | |
Sarah Cavanaugh | F | 49 | 12 years | |
Richard Adcock | M | 55 | 4 years | |
Mitchell Brigell | M | - |
Aerpio Therapeutics, Inc.
![]() Aerpio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aerpio Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases. The firm develops small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Its two lead programs include a tie-2 activator for diabetic macular edema and vascular leak, and a hypoxia-inducible factor 1-a stabilizer for wound healing and the treatment of inflammatory bowel disease. The company was founded by Joseph H. Gardner and Robert Shalwitz in 2011 and is headquartered in Cincinnati, OH. | 7 years |
Karen Shoos | F | 70 | 23 years | |
Stephen Pakola | M | 55 |
Aerpio Therapeutics, Inc.
![]() Aerpio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aerpio Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases. The firm develops small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Its two lead programs include a tie-2 activator for diabetic macular edema and vascular leak, and a hypoxia-inducible factor 1-a stabilizer for wound healing and the treatment of inflammatory bowel disease. The company was founded by Joseph H. Gardner and Robert Shalwitz in 2011 and is headquartered in Cincinnati, OH. | 9 years |
Herbert Conrad | M | 91 | 16 years | |
David-Alexandre Gros | M | 51 | 4 years | |
Kevin G. Peters | M | 67 |
Aerpio Therapeutics, Inc.
![]() Aerpio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aerpio Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases. The firm develops small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Its two lead programs include a tie-2 activator for diabetic macular edema and vascular leak, and a hypoxia-inducible factor 1-a stabilizer for wound healing and the treatment of inflammatory bowel disease. The company was founded by Joseph H. Gardner and Robert Shalwitz in 2011 and is headquartered in Cincinnati, OH. | 11 years |
John Brennan | M | 67 | 3 years | |
Sarah Singleton | F | - | 4 years | |
Rita Jain | M | 62 | 1 years | |
Linda Maxwell | M | 50 | 3 years | |
Jason R. Liljestrom | M | 41 | - | |
Keith Brownlie | M | 71 | 7 years | |
Harry Penner | M | 78 | 27 years | |
Tibor Keler | M | 65 | 41 years | |
James Marino | M | 74 | 7 years | |
Wesley Clark | M | 78 | 3 years | |
Caley Castelein | M | 53 |
Aerpio Therapeutics, Inc.
![]() Aerpio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aerpio Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases. The firm develops small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Its two lead programs include a tie-2 activator for diabetic macular edema and vascular leak, and a hypoxia-inducible factor 1-a stabilizer for wound healing and the treatment of inflammatory bowel disease. The company was founded by Joseph H. Gardner and Robert Shalwitz in 2011 and is headquartered in Cincinnati, OH. | 7 years |
Keith Katkin | M | 52 | 7 years | |
Christobel Selecky | F | 69 | 3 years | |
Garry Neil | M | 70 | 2 years | |
Michael Blaszyk | M | 71 | 9 years | |
Jason Sausser | M | - | 2 years | |
Ronald A. Pepin | M | 68 | 13 years | |
Eric Deng | M | - | 3 years | |
Chris Kontos | M | - |
Aerpio Therapeutics, Inc.
![]() Aerpio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aerpio Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases. The firm develops small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Its two lead programs include a tie-2 activator for diabetic macular edema and vascular leak, and a hypoxia-inducible factor 1-a stabilizer for wound healing and the treatment of inflammatory bowel disease. The company was founded by Joseph H. Gardner and Robert Shalwitz in 2011 and is headquartered in Cincinnati, OH. | - |
Dietmar Vestweber | M | - |
Aerpio Therapeutics, Inc.
![]() Aerpio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aerpio Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases. The firm develops small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Its two lead programs include a tie-2 activator for diabetic macular edema and vascular leak, and a hypoxia-inducible factor 1-a stabilizer for wound healing and the treatment of inflammatory bowel disease. The company was founded by Joseph H. Gardner and Robert Shalwitz in 2011 and is headquartered in Cincinnati, OH. | - |
Helen Luu | F | - | 3 years | |
Freddy Jimenez | M | 55 | 8 years | |
David Sachs | M | 46 | 3 years | |
Leonard Sender | M | - | 4 years | |
Eugene Park | M | - | 3 years | |
Regan Lauer | F | 55 | 3 years | |
Margo Heath-Chiozzi | M | 67 | 7 years | |
Enrique Dilone | M | 57 | 1 years | |
John Lee | M | 56 | 5 years | |
Elizabeth Crowley | F | 52 | 15 years | |
Anne Frese | F | - | 2 years | |
Diane Young | M | 68 | 5 years | |
Richard Wright | M | 60 | 12 years | |
Sandeep K. Reddy | M | - | 4 years | |
Anupam Dalal | M | 52 |
Aerpio Therapeutics, Inc.
![]() Aerpio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aerpio Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases. The firm develops small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Its two lead programs include a tie-2 activator for diabetic macular edema and vascular leak, and a hypoxia-inducible factor 1-a stabilizer for wound healing and the treatment of inflammatory bowel disease. The company was founded by Joseph H. Gardner and Robert Shalwitz in 2011 and is headquartered in Cincinnati, OH. | - |
Hans Klingemann | M | 74 | - | |
Caroline Ruiz | F | - | 2 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Jodie Morrison | F | 48 |
Tokai Pharmaceuticals, Inc.
![]() Tokai Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tokai Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel proprietary therapies for the treatment of prostate cancer and hormonally driven diseases. The company was founded by Joseph A. Yanchik, Gregory L. Verdine, and Seth L. Harrison on March 26, 2004 and is headquartered in Boston, MA. | 12 years |
Muneer Satter | M | 63 |
Vital Therapies, Inc.
![]() Vital Therapies, Inc. Pharmaceuticals: MajorHealth Technology Vital Therapies, Inc. operates as a biotherapeutic company, which develops a cell-based therapy targeting the treatment of acute forms of liver failure. Its product candidate, ELAD System, is a human cell-based bio-artificial liver support system that operates outside the body or extracorporeal. The company was founded in May 2003 and is headquartered in San Diego, CA. | 8 years |
Michael Rogers | M | 64 | 2 years | |
Regina Marek | F | 55 | 3 years | |
Jon S. Kuwahara | M | 59 | 4 years | |
Christine Ocampo | F | 51 | - | |
Gregory Flesher | M | 54 | 3 years | |
Daniel Vitt | M | 55 |
Vital Therapies, Inc.
![]() Vital Therapies, Inc. Pharmaceuticals: MajorHealth Technology Vital Therapies, Inc. operates as a biotherapeutic company, which develops a cell-based therapy targeting the treatment of acute forms of liver failure. Its product candidate, ELAD System, is a human cell-based bio-artificial liver support system that operates outside the body or extracorporeal. The company was founded in May 2003 and is headquartered in San Diego, CA. | - |
Faheem Hasnain | M | 65 |
Vital Therapies, Inc.
![]() Vital Therapies, Inc. Pharmaceuticals: MajorHealth Technology Vital Therapies, Inc. operates as a biotherapeutic company, which develops a cell-based therapy targeting the treatment of acute forms of liver failure. Its product candidate, ELAD System, is a human cell-based bio-artificial liver support system that operates outside the body or extracorporeal. The company was founded in May 2003 and is headquartered in San Diego, CA. | 3 years |
Terence E. Winters | M | 82 |
Vital Therapies, Inc.
![]() Vital Therapies, Inc. Pharmaceuticals: MajorHealth Technology Vital Therapies, Inc. operates as a biotherapeutic company, which develops a cell-based therapy targeting the treatment of acute forms of liver failure. Its product candidate, ELAD System, is a human cell-based bio-artificial liver support system that operates outside the body or extracorporeal. The company was founded in May 2003 and is headquartered in San Diego, CA. | 14 years |
Steven Prelack | M | 66 | 4 years | |
Jennifer J. Rhodes | F | 53 | 3 years | |
Dawn Svoronos | F | 70 | 3 years | |
Michael V. Swanson | M | 69 |
Vital Therapies, Inc.
![]() Vital Therapies, Inc. Pharmaceuticals: MajorHealth Technology Vital Therapies, Inc. operates as a biotherapeutic company, which develops a cell-based therapy targeting the treatment of acute forms of liver failure. Its product candidate, ELAD System, is a human cell-based bio-artificial liver support system that operates outside the body or extracorporeal. The company was founded in May 2003 and is headquartered in San Diego, CA. | 6 years |
Lee Kalowski | M | 43 |
Tokai Pharmaceuticals, Inc.
![]() Tokai Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tokai Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel proprietary therapies for the treatment of prostate cancer and hormonally driven diseases. The company was founded by Joseph A. Yanchik, Gregory L. Verdine, and Seth L. Harrison on March 26, 2004 and is headquartered in Boston, MA. | 2 years |
Douglas Godshall | M | 59 |
Vital Therapies, Inc.
![]() Vital Therapies, Inc. Pharmaceuticals: MajorHealth Technology Vital Therapies, Inc. operates as a biotherapeutic company, which develops a cell-based therapy targeting the treatment of acute forms of liver failure. Its product candidate, ELAD System, is a human cell-based bio-artificial liver support system that operates outside the body or extracorporeal. The company was founded in May 2003 and is headquartered in San Diego, CA. | 5 years |
Manfred Gröppel | M | 55 |
Vital Therapies, Inc.
![]() Vital Therapies, Inc. Pharmaceuticals: MajorHealth Technology Vital Therapies, Inc. operates as a biotherapeutic company, which develops a cell-based therapy targeting the treatment of acute forms of liver failure. Its product candidate, ELAD System, is a human cell-based bio-artificial liver support system that operates outside the body or extracorporeal. The company was founded in May 2003 and is headquartered in San Diego, CA. | - |
J. Michael Millis | M | 65 |
Vital Therapies, Inc.
![]() Vital Therapies, Inc. Pharmaceuticals: MajorHealth Technology Vital Therapies, Inc. operates as a biotherapeutic company, which develops a cell-based therapy targeting the treatment of acute forms of liver failure. Its product candidate, ELAD System, is a human cell-based bio-artificial liver support system that operates outside the body or extracorporeal. The company was founded in May 2003 and is headquartered in San Diego, CA. | 12 years |
Erez Chimovits | M | 60 | 3 years | |
Russell Cox | M | 60 |
Vital Therapies, Inc.
![]() Vital Therapies, Inc. Pharmaceuticals: MajorHealth Technology Vital Therapies, Inc. operates as a biotherapeutic company, which develops a cell-based therapy targeting the treatment of acute forms of liver failure. Its product candidate, ELAD System, is a human cell-based bio-artificial liver support system that operates outside the body or extracorporeal. The company was founded in May 2003 and is headquartered in San Diego, CA. | 1 years |
Ofir Moreno | M | - | 12 years | |
Catherine Turkel | M | 63 | 3 years | |
Dominic Piscitelli | M | 50 | 5 years | |
Pravin Dugel | M | 60 | 4 years | |
Gregory Bailey | M | 68 | 7 years | |
Tony Vernon | M | 69 |
Centocor, Inc.
![]() Centocor, Inc. Medical SpecialtiesHealth Technology Centocor, Inc. manufactures healthcare products. Its products include avakine & reopro. The company was founded in 1979 by Hubert J. P. Schoemaker & Michael A. Wall and is headquartered in Horsham, PA. | 3 years |
Richard A. Bierly | M | 68 | 2 years | |
Benjamin S. Levin | M | 46 | 12 years | |
Kevan E. Clemens | M | 80 | 7 years | |
Joseph Scodari | M | 71 |
Centocor, Inc.
![]() Centocor, Inc. Medical SpecialtiesHealth Technology Centocor, Inc. manufactures healthcare products. Its products include avakine & reopro. The company was founded in 1979 by Hubert J. P. Schoemaker & Michael A. Wall and is headquartered in Horsham, PA. | 3 years |
Sujay Kango | M | 60 | 2 years | |
Louis Yu | M | 73 |
Solvay Pharmaceuticals, Inc.
![]() Solvay Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Solvay Pharmaceuticals, Inc manufactures pharmaceutical products. The company produces therapies for cardi-metabolic, gastroenterological, and neurological disorders. Its brands include Androgel, Klonopin, and ACEON drugs. Solvay Pharmaceuticals was founded by Ernest Solvay in 1863 and is located in Marietta, GA. | 3 years |
Rohan Palekar | M | 58 |
Centocor, Inc.
![]() Centocor, Inc. Medical SpecialtiesHealth Technology Centocor, Inc. manufactures healthcare products. Its products include avakine & reopro. The company was founded in 1979 by Hubert J. P. Schoemaker & Michael A. Wall and is headquartered in Horsham, PA. | 10 years |
Timothy Barberich | M | 76 |
Tokai Pharmaceuticals, Inc.
![]() Tokai Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tokai Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel proprietary therapies for the treatment of prostate cancer and hormonally driven diseases. The company was founded by Joseph A. Yanchik, Gregory L. Verdine, and Seth L. Harrison on March 26, 2004 and is headquartered in Boston, MA. | 8 years |
Errol Halperin | M | 83 |
Vital Therapies, Inc.
![]() Vital Therapies, Inc. Pharmaceuticals: MajorHealth Technology Vital Therapies, Inc. operates as a biotherapeutic company, which develops a cell-based therapy targeting the treatment of acute forms of liver failure. Its product candidate, ELAD System, is a human cell-based bio-artificial liver support system that operates outside the body or extracorporeal. The company was founded in May 2003 and is headquartered in San Diego, CA. | 6 years |
Jean-Jacques Bienaimé | M | 70 |
Vital Therapies, Inc.
![]() Vital Therapies, Inc. Pharmaceuticals: MajorHealth Technology Vital Therapies, Inc. operates as a biotherapeutic company, which develops a cell-based therapy targeting the treatment of acute forms of liver failure. Its product candidate, ELAD System, is a human cell-based bio-artificial liver support system that operates outside the body or extracorporeal. The company was founded in May 2003 and is headquartered in San Diego, CA. | 5 years |
Lowell E. Sears | M | 73 |
Vital Therapies, Inc.
![]() Vital Therapies, Inc. Pharmaceuticals: MajorHealth Technology Vital Therapies, Inc. operates as a biotherapeutic company, which develops a cell-based therapy targeting the treatment of acute forms of liver failure. Its product candidate, ELAD System, is a human cell-based bio-artificial liver support system that operates outside the body or extracorporeal. The company was founded in May 2003 and is headquartered in San Diego, CA. | 6 years |
Gary Lyons | M | 73 | 6 years | |
John Dunn | M | 72 |
Vital Therapies, Inc.
![]() Vital Therapies, Inc. Pharmaceuticals: MajorHealth Technology Vital Therapies, Inc. operates as a biotherapeutic company, which develops a cell-based therapy targeting the treatment of acute forms of liver failure. Its product candidate, ELAD System, is a human cell-based bio-artificial liver support system that operates outside the body or extracorporeal. The company was founded in May 2003 and is headquartered in San Diego, CA. | 5 years |
Kathryn Falberg | F | 63 | 3 years | |
Stephen Hoffman | M | 70 | 2 years | |
Wendy Yarno | F | 68 | 3 years | |
Greg Harriman | M | - |
Centocor, Inc.
![]() Centocor, Inc. Medical SpecialtiesHealth Technology Centocor, Inc. manufactures healthcare products. Its products include avakine & reopro. The company was founded in 1979 by Hubert J. P. Schoemaker & Michael A. Wall and is headquartered in Horsham, PA. | 3 years |
David P. Holveck | M | 79 |
Centocor, Inc.
![]() Centocor, Inc. Medical SpecialtiesHealth Technology Centocor, Inc. manufactures healthcare products. Its products include avakine & reopro. The company was founded in 1979 by Hubert J. P. Schoemaker & Michael A. Wall and is headquartered in Horsham, PA. | 16 years |
Dominic Caruso | M | 66 |
Centocor, Inc.
![]() Centocor, Inc. Medical SpecialtiesHealth Technology Centocor, Inc. manufactures healthcare products. Its products include avakine & reopro. The company was founded in 1979 by Hubert J. P. Schoemaker & Michael A. Wall and is headquartered in Horsham, PA. | 14 years |
Rick Anderson | M | 63 |
Centocor, Inc.
![]() Centocor, Inc. Medical SpecialtiesHealth Technology Centocor, Inc. manufactures healthcare products. Its products include avakine & reopro. The company was founded in 1979 by Hubert J. P. Schoemaker & Michael A. Wall and is headquartered in Horsham, PA. | - |
Christian Schneider | M | - |
Centocor, Inc.
![]() Centocor, Inc. Medical SpecialtiesHealth Technology Centocor, Inc. manufactures healthcare products. Its products include avakine & reopro. The company was founded in 1979 by Hubert J. P. Schoemaker & Michael A. Wall and is headquartered in Horsham, PA. | 5 years |
Sally D. Bolmer | M | - |
Centocor, Inc.
![]() Centocor, Inc. Medical SpecialtiesHealth Technology Centocor, Inc. manufactures healthcare products. Its products include avakine & reopro. The company was founded in 1979 by Hubert J. P. Schoemaker & Michael A. Wall and is headquartered in Horsham, PA. | 14 years |
Alejandro Ricart | M | - | 1 years |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 100 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Cheryl Cohen
- Personal Network